Clinical Significance of IgA Anti-Cardiolipin and IgA Anti-[bet[a].sub.2]Glycoprotein I Antibodies

Citation metadata

From: Current Rheumatology Reports(Vol. 15, Issue 7)
Publisher: Springer
Document Type: Report
Length: 273 words

Document controls

Main content

Abstract :

Byline: Laura Andreoli (1), Micaela Fredi (1,2), Cecilia Nalli (1,2), Silvia Piantoni (1,2), Rossella Reggia (1,2), Francesca Dall'Ara (1,2), Franco Franceschini (3), Angela Tincani (1) Keywords: Anti-phospholipid antibodies; Anti-cardiolipin antibodies; Anti-[beta]2glycoprotein I antibodies; Lupus anticoagulant; IgA antibodies; Thrombosis; Pregnancy loss; Stroke; Primary antiphospholipid syndrome; Systemic lupus erythematosus; Pathogenic anti-phospholipid antibodies; Domains of [beta]2glycoprotein I; Classification criteria Abstract: IgA antiphospholipid antibodies (aPL) are not currently recognized as formal laboratory criteria for the Antiphospholipid Syndrome (APS). This is mainly due to methodological issues (different study designs, use of various non-standardized IgA assays). However, there are experimental data showing the pathogenic role of IgA anti-cardiolipin antibodies (aCL) and IgA anti-[beta]2glycoprotein I antibodies (anti-[beta]2GPI). Isolated IgA aCL are not very common, therefore their testing could be useful in the case of strong suspicion of APS but negative results for other aPL tests. IgA anti-[beta]2GPI seem to be the most prevalent isotype in patients with Systemic Lupus Erythematosus (SLE), with a significant association with thrombotic events. Such a clinical relevance has been recently recognized by the inclusion of these autoantibodies among the aPL tests in the novel SLICC classification criteria for SLE. Emerging interest has been raised by IgA anti-[beta]2GPI against domain 4/5 as a novel subgroup of clinically relevant aPL. Author Affiliation: (1) Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, Spedali Civili and University of Brescia, Piazzale Spedali Civili 1, 25123, Brescia, Italy (2) Rheumatology Chair, University of Pavia, Pavia, Italy (3) Rheumatology and Clinical Immunology, Piazzale Spedali Civili 1, 25123, Brescia, Italy Article History: Registration Date: 24/04/2013 Online Date: 11/06/2013 Article note: This article is part of the Topical Collection on Antiphospholipid Syndrome

Source Citation

Source Citation   

Gale Document Number: GALE|A334692190